Financials data is unavailable for this security.
View more
Year on year Seres Therapeutics Inc grew revenues 1,672.24% from 7.13m to 126.33m while net income improved from a loss of 250.16m to a smaller loss of 113.72m.
| Gross margin | -- |
|---|---|
| Net profit margin | -258,259.40% |
| Operating margin | -218,167.20% |
| Return on assets | -60.50% |
|---|---|
| Return on equity | -3,758.21% |
| Return on investment | -82.15% |
More ▼
Cash flow in USDView more
In 2023, cash reserves at Seres Therapeutics Inc fell by 35.07m. Cash Flow from Financing totalled 71.71m or 56.76% of revenues. In addition the company used 117.36m for operations while cash from investing totalled 10.58m.
| Cash flow per share | -1.10 |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 0.1405 |
|---|---|
| Tangible book value per share | 0.1405 |
More ▼
Balance sheet in USDView more
| Current ratio | 1.12 |
|---|---|
| Quick ratio | -- |
| Total debt/total equity | 0.00 |
|---|---|
| Total debt/total capital | 0.00 |
More ▼
